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Summary
Background Between 1990 and 2000, we examined the eﬀ ect of timing of non-platinum chemotherapy when combined 
with radiotherapy. We aimed to determine whether giving chemotherapy concurrently with radiotherapy or as 
maintenance therapy, or both, aﬀ ected clinical outcome. Here we report survival and recurrence after 10 years of 
follow-up. 
Methods Between Jan 15, 1990, and June 20, 2000, 966 patients were recruited from 34 centres in the UK and two 
centres from Malta and Turkey. Patients with locally advanced head and neck cancer, and who had not previously 
undergone surgery, were randomly assigned to one of four groups in a 3:2:2:2 ratio, stratiﬁ ed by centre and 
chemotherapy regimen: radical radiotherapy alone (n=233); radiotherapy with two courses of chemotherapy given 
simultaneously on days 1 and 14 of radiotherapy (SIM alone; n=166); or 14 and 28 days after completing radiotherapy 
(SUB alone, n=160); or both (SIM+SUB; n=154). Chemotherapy was either methotrexate alone, or vincristine, 
bleomycin, methotrexate, and ﬂ uorouracil. Patients who had previously undergone radical surgery to remove their 
tumour were only randomised to radiotherapy alone (n=135) or SIM alone (n=118), in a 3:2 ratio. The primary 
endpoints were overall survival (from randomisation), and event-free survival (EFS; recurrence, new tumour, or 
death; whichever occurred ﬁ rst) among patients who were disease-free 6 months after randomisation. Analyses were 
by intention to treat. This trial is registered at www.Clinicaltrials.gov, number NCT00002476.
Findings All 966 patients were included in the analyses. Among patients who did not undergo surgery, the median 
overall survival was 2·6 years (99% CI 1·9–4·2) in the radiotherapy alone group, 4·7 (2·6–7·8) years in the SIM alone 
group, 2·3 (1·6–3·5) years in the SUB alone group, and 2·7 (1·6–4·7) years in the SIM+SUB group (p=0·10). The 
corresponding median EFS were 1·0 (0·7–1·4), 2·2 (1·1–6·0), 1·0 (0·6–1·5), and 1·0 (0·6–2·0) years (p=0·005), 
respectively. For every 100 patients given SIM alone, there are 11 fewer EFS events (99% CI 1–21), compared with 100 
given radiotherapy, 10 years after treatment. Among the patients who had previously undergone surgery, median 
overall survival was 5·0 (99% CI 1·8–8·0) and 4·6 (2·2–7·6) years in the radiotherapy alone and SIM alone groups 
(p=0·70), respectively, with corresponding median EFS of 3·7 (99% CI 1·1–5·9) and 3·0 (1·2–5·6) years (p=0·85), 
respectively. The percentage of patients who had a signiﬁ cant toxicity during treatment were: 11% (radiotherapy alone, 
n=25), 28% (SIM alone, n=47), 12% (SUB alone, n=19), and 36% (SIM+SUB, n=55) among patients without previous 
surgery; and 9% (radiotherapy alone, n=12) and 20% (SIM alone, n=24) among those who had undergone previous 
surgery. The most common toxicity during treatment was mucositis. The percentage of patients who had a signiﬁ cant 
toxicity at least 6 months after randomisation were: 6% (radiotherapy alone, n=13), 6% (SIM alone, n=10), 4% (SUB 
alone, n=7), and 6% (SIM+SUB, n=9) among patients who had no previous surgery; and 7% (radiotherapy alone, 
n=10) and 11% (SIM alone, n=13) among those who had undergone previous surgery. The most common toxicity 
6 months after treatment was xerostomia, but this occurred in 3% or less of patients in each group.
Interpretation Concurrent non-platinum chemoradiotherapy reduces recurrences, new tumours, and deaths in 
patients who have not undergone previous surgery, even 10 years after starting treatment. Chemotherapy given after 
radiotherapy (with or without concurrent chemotherapy) is ineﬀ ective. Patients who have undergone previous surgery 
for head and neck cancer do not beneﬁ t from non-platinum chemotherapy.
Funding Cancer Research UK, with support from University College London and University College London Hospital 
Comprehensive Biomedical Research Centre.
Introduction
Head and neck cancers are relatively common (about 
7500 new cases in the UK and 45 000 in the US each 
year), and are increasing in incidence in some countries 
such as the UK, mainly because of smoking and 
excessive alcohol intake.1–3 Standard treatment until 
1990 was surgical resection or radical radiotherapy, 
sometimes both. The role of chemotherapy has been 
investigated for over 20 years, but with varying reports 
of eﬀ ectiveness. Toxicity is especially important since 
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patients are typically unﬁ t, often with coexistent 
illness.4,5 
Over the past decade the role of chemotherapy has 
become clearer. A meta-analysis published in 20006 and 
updated in 20097 indicated that concomitant chemo-
therapy reduced the risk of dying by 19% compared with 
radiotherapy alone. The number of agents found to be 
active in squamous-cell carcinoma has increased, and the 
best ways of combining them continue to be investigated.
The UK Head and Neck (UKHAN) cancer group was 
established in 1990 to investigate the eﬀ ectiveness of 
chemotherapy used in conjunction with radiotherapy and 
surgery. At the time, it was believed that chemotherapy 
given at the same time as radical radiotherapy 
(ie, concurrent) and afterwards (ie, maintenance) could be 
eﬀ ective. The UKHAN1 trial was designed to determine 
whether adding chemotherapy to standard radical treat-
ment—radiotherapy with or without primary surgery—
would improve survival and loco-regional control. Other 
objectives were to assess the eﬀ ect of timing and duration 
of chemotherapy—ie, whether two courses should be 
given simultaneously with (SIM alone) or subsequent to 
(SUB alone) the radiotherapy course, or both simultaneously 
and following radiotherapy (four courses, SIM+SUB). 
Earlier results were presented and reported in 2001.8 Here 
we report the results after 10 years of follow-up. 
Methods
Patients
Patients with locally advanced squamous-cell carcinoma 
of the head and neck were included in a factorial 
randomised trial if they were judged to be suitable for 
radical radiotherapy as either initial treatment or 
following an operation (generally patients at high risk of 
recurrence following surgery due to margin status or 
advanced stage of disease at presentation). 
Before participating in the trial, patients underwent a 
full clinical head and neck examination, with biopsy or 
surgical resection of the primary tumour and chest 
radiography. Patients were eligible if they satisﬁ ed the 
following criteria: age 18 years or over; considered ﬁ t 
enough to receive any of the trial treatments; had 
histological conﬁ rmation of squamous-cell carcinoma, 
with T2 to T4 primary lesions (including node-negative 
cases) or were node positive; had full normal blood count, 
and creatinine and urea levels within normal ranges; 
showed no evidence of distant metastases; and had no 
previous treatment for the cancer other than surgical 
excision. Ethical approval was obtained from each centre. 
All patients gave written informed consent.
Procedures
The extent of previous surgery, radiotherapy regimen, 
and nutritional support with either nasogastric or per-
cutaneous-endoscopic radiologically inserted gastrostomy 
feeding, were based on local policies to maximise 
recruitment. Investigators declared their radiotherapy 
treatment policy prospectively before participating. 
Surgery before randomisation was also determined by 
local practice, and could involve resection of the primary 
tumour alone with or without comprehensive neck-node 
resection, provided that the intention was to completely 
713 patients had no surgery
233 patients allocated to 
radiotherapy alone
5 patients ineligible
 1 early stage disease
 2 ineligible history
 1 previous treatment
 1 other
233 patients analysed
178 events for overall survival
197 events for EFS 125 events for EFS 141 events for EFS 132 events for EFS 103 events for EFS 89 events for EFS
115 events for overall survival 128 events for overall survival 122 events for overall survival 95 events for overall survival 79 events for overall survival
166 patients analysed 160 patients analysed 154 patients analysed 135 patients analysed 118 patients analysed
7 patients ineligible
 1 early stage disease
 3 ineligible history
 1 previous treatment
 2 other
14 non-compliers to 
chemotherapy*
50 non-compliers to 
chemotherapy*
68 non-compliers to 
chemotherapy*
32 non-compliers to 
chemotherapy*
9 patients ineligible
 1 early-stage disease
 2 occult primary
 1 ineligible history
 3 previous treatment
 2 other
5 patients ineligible
 1 early stage disease
 2 previous treatment
 2 other
1 patients ineligible
 1 early stage disease
166 patients allocated to 
SIM alone
135 patients allocated to 
radiotherapy alone
118 patients allocated to 
SIM alone
160 patients allocated to 
SUB alone
154 patients allocated to 
SIM+SUB
253 patients had surgery
Figure 1: Trial proﬁ le
EFS=event-free survival. SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 
and 28 days after completing radiotherapy. *See table 2. Only 26 patients did not fully meet the eligibility criteria, but they were included in the analysis.
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clear the tumour. Usually at the outset these surgery 
patients were scheduled for adjunctive postoperative 
radiotherapy because of their advanced disease.
Although radical radiotherapy could be given according 
to local practice, it had to be approved by the trial steering 
committee, and investigators were asked to adhere to it 
for all patients within that centre, regardless of treatment 
allocation. Two extensively tested regimens were recom-
mended9–11 (webappendix). The Manchester regimen 
involved a radical course to the primary tumour and 
lymph nodes in 15 or 16 fractions (ﬁ ve fractions per week) 
over 3–3·5 weeks. Treatment volume was kept to a 
minimum, and no attempt was made to encompass the 
entire regional lymphatic drainage areas. The minimum 
tumour dose was in the range of 50–55 Gy for a ﬁ eld area 
of 25–40 cm², reduced to 45 Gy for larger ﬁ elds. The 
South-East Co-operative Oncology Group regimen 
involved irradiation with planned ﬁ elds to adequately 
cover the primary tumour in unresected cases, and in 
most cases the lymph-node drainage area. The 
recommended fractionation was 1·8–2 Gy daily, 5 days 
per week, to a minimum total dose of 60 Gy, although 
higher doses were permitted. Another common regimen, 
used in Birmingham, Edinburgh, and some other centres, 
had the following schedule: 55 Gy given in 20 fractions 
(2·75 Gy per fraction) over 4 weeks to the primary tumour 
and ﬁ rst station lymphatic drainage, and 41·25 Gy in 
15 fractions to the elective neck. 50 Gy given in 20 fractions 
(2·5 Gy per fraction) was given postoperatively.
Chemotherapy regimens were either methotrexate 
alone or vincristine, bleomycin, methotrexate, and 
ﬂ uorouracil (VBMF); webappendix.8,9 SIM started on 
days 1 and 14 concurrently with radiotherapy, and SUB 
started 14 and 28 days after completing radiotherapy. 
Methotrexate was given intravenously in two doses of 
100 mg/m²: the ﬁ rst dose was given 24 h before 
radiotherapy and the second dose was given on day 14 
of radiotherapy. Folinic acid rescue was given if serum 
methotrexate concentration at 24 h after treatment 
exceeded 0·4 μmol/L.10 VBMF consisted of vincristine 
1·4 mg/m² (maximum 2 mg), bleomycin 30 mg, 
ﬂ uorouracil 500 mg, and methotrexate 100 mg/m². 
Drugs were given intravenously by slow bolus injection 
except bleomycin, which was given by intramuscular 
injection. Hydrocortisone (100 mg intramuscular 
injection) could be given to minimise the risk of 
bleomycin reactions, and anti-emetics were given 
according to local practice. 
Primary endpoints were overall survival, measured 
from the time from randomisation to death from any 
cause, and event-free survival (EFS), deﬁ ned as recurrence, 
new tumour, or death (whichever occurred ﬁ rst) among 
patients who were disease-free 6 months after 
randomisation. Nine patients who had salvage treatment 
after being disease free, but without a recorded date of 
recurrence, were counted as a suspected recurrence. 
Other endpoints were control of local and regional disease 
(ie, the complete remission rate) at 6 months; time to 
recurrence; death from head and neck cancer; and toxicity 
during and after treatment, which was classiﬁ ed as 
signiﬁ cant if hospitalisation was required during 
chemoradiation, therapy was required to alleviate chronic 
treatment-related toxicity (eg, dilatations for oesophageal 
strictures), or clinicians recorded an event as severe after 
treatment. Although toxicity was not recorded on a 
standardised scale during the trial, we compared the 
reported adverse-event grading and descriptions with the 
Common Terminology Criteria for Adverse Events 
(CTCAE) version 3, as part of the statistical analysis. 
A signiﬁ cant event was generally comparable to a grade 3 
or 4 CTCAE event (mostly grade 3). Compliance with 
radiotherapy or chemotherapy was determined: 
No previous surgery (N=713) Surgery (N=253)
Radiotherapy 
alone 
(N=233)
SIM alone 
(N=166)
SUB alone 
(N=160)
SIM+SUB 
(N=154)
Radiotherapy 
alone 
(N=135)
SIM alone 
(N=118)
Age (years; median 
and range)
60 (17–78) 59 (29–78) 60 (34–82) 60 (26–84) 56 (32–76) 60 (36–81)
Sex
Male 188 (81) 125 (75) 119 (74) 134 (87) 104 (77) 88 (75)
Female 45 (19) 40 (24) 40 (25) 19 (12) 31 (23) 30 (25)
Tumour stage
T1 19 (8) 10 (6) 11 (7) 8 (5) 7 (5) 8 (7)
T2 106 (46) 72 (43) 64 (40) 56 (36) 22 (16) 29 (25)
T3 52 (22) 45 (27) 35 (22) 49 (32) 27 (20) 26 (22)
T4 56 (24) 38 (23) 50 (31) 39 (25) 76 (56) 54 (46)
Unknown 0 1 (<1) 0 2 (1) 3 (2) 1 (<1)
Nodal status
Negative 129 (55) 88 (53) 95 (59) 80 (52) 58 (43) 39 (33)
Positive 104 (45) 77 (46) 65 (41) 73 (47) 76 (56) 78 (66)
Unknown 0 1 (<1) 0 1 1 (<1) 1 (<1)
Stage
Stage II 64 (27) 47 (28) 47 (29) 36 (23) 6 (4) 10 (8)
Stage III 71 (30) 53 (32) 40 (25) 49 (32) 26 (19) 25 (21)
Stage IV 97 (42) 63 (38) 72 (45) 66 (43) 98 (73) 81 (69)
Unknown 1 (<1) 3 (2) 2 (1) 1 (<1) 5 (4) 2 (2)
Site of primary
Larynx 73 (31) 51 (31) 54 (34) 46 (30) 28 (21) 34 (29)
Oral cavity 41 (18) 18 (11) 20 (13) 19 (12) 46 (34) 43 (36)
Oropharynx 78 (34) 65 (39) 53 (33) 60 (39) 34 (25) 25 (21)
Nasopharynx 14 (6) 13 (8) 12 (8) 11 (7) 2 (1) 2 (2)
Hypopharynx 22 (9) 14 (8) 14 (9) 17 (11) 18 (13) 11 (9)
Other 5 (2) 5 (3) 7 (4) 1 (<1) 7 (5) 3 (3)
Unknown 0 0 0 0 1 (<1) 0
Surgery group
Margins cleared* ·· ·· ·· ·· 64 (47) 56 (47)
Neck dissection 
done
·· ·· ·· ·· 94 (70) 88 (74)
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= 
radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. Data are n (%), 
unless stated otherwise. *Primary site resection margins were clear.
Table 1: Distribution of baseline characteristics according to trial group
See Online for webappendix
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a non-complier was deﬁ ned as a patient who did not 
receive the full dose according to the trial protocol. In 
October, 2008, an active data chase was completed to 
ascertain which patients had died or had a recurrence or 
new tumour, and the date patients were last seen alive.
Randomisation and masking
Block stratiﬁ ed randomisation was used, and allocations 
were concealed from investigators and patients by 
generating random number lists centrally at the 
coordinating centre (Cancer Research UK and University 
College London Cancer Trials Centre). Patients were to be 
allocated to radiotherapy alone, SIM alone, SUB alone or 
SIM+SUB if they had not had previous surgery, using a 
block size of nine (allocation ratio 3:2:2:2, which is 1:2 in 
favour of chemotherapy, to increase the total number of 
patients given chemotherapy); or only to radiotherapy 
alone or SIM alone if they had previously undergone 
surgery, using a block size of ﬁ ve (allocation ratio 3:2). 
Randomisation stratiﬁ cation factors were centre (which 
automatically stratiﬁ es for radiotherapy regimen and all 
other local policies for patient management) and 
chemotherapy regimen (though all but two centres used a 
single regimen during the trial). Hospital clinicians 
recruited patients, and centres telephoned the co-ordinating 
centre, who assigned each patient a treatment allocation 
after recording the eligibility and stratiﬁ cation factors.
Statistical analysis
The sample size of about 1000 patients was based on 
detecting an increase in 5-year survival from 25% in the 
radiotherapy-alone group to 35% in the chemotherapy 
groups combined, with 90% power and two-sided 5% 
level of statistical signiﬁ cance. Statistical analyses were 
by intention to treat and based on the log-rank test. 
Hazard ratios (HR) are reported separately for patients 
who had or had not undergone previous surgery. All 
p values are two-sided, and 99% CI were used to allow for 
having multiple comparisons (95% for the primary 
objective of any chemotherapy versus radiotherapy 
alone). Patients not disease-free by 6 months after 
randomisation were counted as having an event at time 
zero for the EFS analysis. All analyses were done using 
STATA version 10. This trial is registered with www.
ClinicalTrials.gov, number NCT00002476.
Role of the funding source
The funding organisation (Cancer Research UK) 
approved the study design but had no involvement in the 
collection, analysis, or interpretation of the data, or the 
writing of this report. The corresponding author had full 
access to all of the data and the ﬁ nal responsibility to 
submit the manuscript for publication.
Results
Between Jan 15, 1990, and June 20, 2000, 966 patients were 
recruited from 34 centres in the UK and two from Malta 
No previous surgery (N=713) Surgery (N=253)
Radiotherapy 
alone 
(N=233)
SIM alone 
(N=166) 
SUB 
alone 
(N=160)
SIM+SUB 
(N=154)
Radiotherapy 
alone 
(N=135)
SIM 
alone 
(N=118)
Radiotherapy non-compliance
Disease progression 3 (1) 4 (2) 1 (<1) 1 (<1) 1 (<1) 3 (3)
Deaths 2 (<1) 3 (2) 0 6 (4) 2 (2) 2 (2)
Treatment-related deaths 1 (<1) 0 0 3 (2) 0 0
Toxicity 2 (<1) 0 0 1 (<1) 0 3 (3)
Patient withdrew 1 (<1) 0 2 (1) 0 2 (2) 0
Other 7 (3) 7 (4) 3 (2) 5 (3) 2 (2) 2 (2)
Data missing 0 0 2 (1) 0 2 (2) 1 (<1)
Total non-compliers* 16 (7) 14 (8) 6 (4) 16 (10) 7 (5) 10 (8)
Chemotherapy non-compliance
Disease progression NA 4 (2) 11 (7) 7 (5) NA 4 (3)
Patient not ﬁ t enough NA 0 2 (1) 0 NA 1 (<1)
Deaths NA 0 6 (4) 8 (5) NA 1 (<1)
Treatment-related deaths NA 0 2 (1) 8 (5) NA 0
Toxicity NA 3 (2) 8 (5) 24 (16) NA 14 (12)
Reduced renal function NA 1 (<1) 4 (3) 7 (5) NA 0
Patient withdrew NA 2 (1) 8 (5) 10 (6) NA 6 (5)
Other NA 4 (2) 9 (6) 4 (3) NA 6 (5)
Data missing NA 0 2 (1) 1 (<1) NA 2 (2)
Total non-compliers* NA 14 (8) 50 (31) 68 (44) NA 32 (27)
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. 
SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. NA=not 
applicable. Data are n (%). *Excluding those with missing data.
Table 2: Reasons for not complying with the scheduled radiotherapy and chemotherapy regimen 
speciﬁ ed in the trial protocol (did not receive the full dose, or did not receive the therapy at all)
No previous surgery (N=713) Surgery (N=253)
Radiotherapy 
alone 
(N=233)
SIM alone
(N=166)
SUB alone
(N=160)
SIM+SUB
(N=154)
Radiotherapy 
alone
(N=135)
SIM alone
(N=118)
Cause of death
Treatment-related* 1 (0·4) 1 (0·6) 2 (1·2) 8 (5·2) 0 0
Post-operative deaths 2 (0·8) 0 3 (1·9) 0 3 (2·2) 0
Head and neck cancer 120 (51) 83 (50) 95 (59) 72 (47) 66 (49) 55 (47)
Not cancer related 47 (20) 25 (15) 25 (16) 34 (22) 22 (16) 21 (18)
Uncertain 8 (3·4) 6 (3·6) 3 (1·9) 8 (5·2) 4 (3·0) 3 (2·5)
Total deaths 178 115 128 122 95 79
Disease-free at 6 months† 146 (63) 122 (73) 106 (66) 95 (62) 102 (76) 91 (77)
First event‡
Recurrence 57 (39) 39 (32) 50 (47) 35 (37) 23 (22) 25 (27)
Death 31 (21) 28 (23) 18 (17) 23 (24) 25 (24) 18 (20)
New tumour 22 (15) 14 (11) 19 (18) 15 (14) 22 (22) 19 (21)
Total ﬁ rst events 110 81 87 73 70 62
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. 
SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. Data are n 
(%). *Radiotherapy or chemotherapy. †Expressed as a percentage of all patients randomised to the group. ‡Expressed 
as a percentage of the number disease free at 6 months.
Table 3: The number and causes of death, and the number of ﬁ rst events in patients who were 
disease free at 6 months after randomisation (used to examine event-free survival), according to 
trial group
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and Turkey. The median length of follow-up was 10 years 
after censoring those who had died (maximum of 17 years), 
with 4397 person-years in total. No data were available for 
only 89 patients after 2005. The trial proﬁ le is shown in 
ﬁ gure 1; baseline characteristics are shown in table 1.
7% of patients (69/966) were known to have not 
completed the planned radiotherapy course (table 2). 27% 
of patients (164/598) allocated to receive chemotherapy 
did not complete their full course of treatment, mainly 
due to disease progression, acute toxicity, or withdrawal 
from treatment. Among patients without prior surgery, 
only 8% (14/166) of the SIM alone group were 
non-compliers to chemotherapy, compared with 31% 
(50/160) and 44% (68/154) in the SUB alone and SIM+SUB 
groups respectively. 27% (32/118) of SIM alone patients 
who had surgery did not complete their chemotherapy.
69% (662/966) of patients were disease-free at 6 months 
(webappendix). Among those without previous surgery, 
the proportion disease-free at 6 months was highest in 
the SIM alone group (73%, 122/166) compared with the 
other groups: radiotherapy alone (63%, 146/233), SUB 
alone (66%, 106/160), and SIM+SUB (62%, 95/154). 
There was little diﬀ erence among patients who had 
undergone previous surgery: radiotherapy alone (76%, 
102/135) and SIM alone (77%, 91/118).
There were 717 deaths among all 966 patients, and 
483 EFS events among the 662 patients who were disease 
free at 6 months (table 3). Estimated 5-year overall survival 
was 43% (95% CI 38–48) and EFS was 32% (27–37) in the 
radiotherapy-alone group (patients with or without 
previous surgery). There was no eﬀ ect on overall survival 
or EFS for any chemotherapy (ie, combining SIM alone, 
SUB alone, and SIM+SUB). Compared with radiotherapy 
alone, the overall survival and EFS HR for any 
chemotherapy were 0·97 (95% CI 0·83–1·13, p=0·71) and 
0·92 (0·79–1·06; p=0·25), respectively. However, because 
the eﬀ ects of SIM and SUB clearly diﬀ ered, they need to be 
considered separately. The chemotherapy or radiotherapy 
regimen used did not aﬀ ect the results (webappendix).
Kaplan–Meier curves for overall survival and EFS are 
shown in ﬁ gures 2 and 3. In patients without previous 
surgery, median overall survival was 2·6 (99% CI 
1·9–4·2) years for those allocated to radiotherapy alone, 
4·7 (2·6–7·8) years for SIM alone, 2·3 (1·6–3·5) years 
for SUB alone, and 2·7 (1·6–4·7) years in those allocated 
to SIM+SUB (log-rank p=0·10). The corresponding 
median EFS was 1·0 (0·7–1·4), 2·2 (1·1–6·0), 1·0 
(0·6–1·5), and 1·0 (0·6–2·0) years (log-rank p=0·005). 
Forest plots for EFS, overall survival, time to recurrence, 
and death from head and neck cancer for various 
treatment comparisons are shown in the webappendix. 
Compared with radiotherapy alone, SIM alone was 
associated with an improvement in EFS (HR 0·72, 99% 
CI 0·53–0·96; p=0·004), although the eﬀ ect on overall 
survival was not signiﬁ cant (0·82, 0·60–1·11; p=0·09). 
Estimated 5-year overall survival and EFS in the 
SIM-alone group were 50% (95% CI 39–59) and 42% 
(32–52; the corresponding rates in the radiotherapy alone 
group were 39% [31–48] and 24% [17–31]). There was no 
evidence of a survival beneﬁ t for either SUB alone (overall 
survival HR 1·10 [0·81–1·48]; p=0·42) or SIM+SUB 
(overall survival HR 1·06 [0·78–1·44]; p=0·62). 
Comparing four with two courses of chemotherapy (ie, 
SIM+SUB vs either SIM alone or SUB alone) did not 
show a survival advantage (webappendix). Adding SUB 
to SIM seemed to reduce the beneﬁ t of SIM, producing a 
higher rate of death and events: compared with SIM 
alone, overall survival (HR 1·29; 99% CI 0·92–1·81; 
p=0·049) and EFS (HR 1·27, 0·92–1·75; p=0·06). HR 
from an analysis of the main eﬀ ects associated with a 2×2 
factorial trial (ie, any SIM vs no SIM, and any SUB vs no 
SUB [test for the interaction between SIM and SUB 
p=0·12], as well as SIM alone vs SUB alone, and 
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Figure 2: Overall survival according to treatment groups for patients who had no surgery (A) and those who 
had undergone surgery (B) before randomisation
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. 
SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy.
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radiotherapy alone vs SIM alone or SUB alone), are 
shown in the webappendix.
Adding chemotherapy to radiotherapy was not 
eﬀ ective in patients who had undergone surgery 
previously. The median overall survival was 4·6 (99% 
CI 2·2–7·6) and 5·0 (1·8–8·0) years in those allocated 
to SIM alone or radiotherapy alone, respectively 
(HR 0·94, 99% CI 0·64–1·40; p=0·70). The median EFS 
was 3·0 (99% CI 1·2–5·6) years and 3·7 (1·1–5·9) years 
in the SIM-alone and radiotherapy-alone group 
(HR 1·03, 99% CI 0·71–1·49; p=0·85). The median 
overall survival associated with SIM alone was similar 
to the corresponding SIM group without previous 
surgery (4·6 vs 4·7 years), but the median EFS was 
higher (3·0 vs 2·2 years).
Estimated absolute risk diﬀ erences for overall survival, 
EFS, and recurrence at 5 and 10 years after randomisation 
are shown in table 4. Compared with radiotherapy alone, 
for every 100 patients given SIM alone, there could be 
10·6 fewer patients who have a recurrence, new tumour, 
or die by 10 years after treatment (99% CI 1·1–21·2 fewer); 
equivalent to a number needed to treat of nine patients to 
avoid one event at 10 years. Similar eﬀ ects were seen for 
overall survival. There could be 7·1 fewer deaths at 
10 years (99% CI 18·4 fewer to 3·5 more) among 
100 patients treated with SIM alone (number needed to 
treat of 14). No beneﬁ t was seen with SUB alone or 
SIM+SUB, consistent with the other results.
The percentages of patients who had a signiﬁ cant 
toxicity during treatment requiring hospitalisation in 
patients without previous surgery was 11% (25/233) 
in patients allocated to radiotherapy alone, 28% (47/166) in 
patients allocated to SIM alone, 12% (19/160) in patients 
allocated to SUB alone, and 36% (55/154) in patients 
allocated to SIM+SUB (table 5). The toxicity rates did not 
diﬀ er substantially between the type of chemotherapy 
used (methotrexate or VBMF; table 5). Although 28% of 
patients in the SIM-alone group had an acute toxicity, 
compliance to chemotherapy was high (92%, 152/166; 
table 2), probably because being in hospital would have 
provided them with the appropriate care to continue 
treatment. For patients who had undergone previous 
surgery, SIM alone was associated with a doubling in the 
acute toxicity rate: 20% (24/118) SIM alone versus 9% 
(12/135) radiotherapy alone. Patients in the SIM+SUB 
group who experienced acute toxicity during 
chemoradiation were less likely to complete their allocated 
chemotherapy regimen (table 2).
Signiﬁ cant late toxicity occurring 6 months or more 
after randomisation was reported in 62 patients in total; 
44% (n=27) of ﬁ rst notiﬁ cations occurring in months 
6–11·9, and 24% (n=15) occurring in months 12–24. The 
rates were similar between the trial groups: 6% (13/233) 
among patients without surgery allocated to radiotherapy 
alone, 6% (10/166) for those allocated to SIM alone, 
4% (7/160) for those allocated to SUB alone, and 6% 
(9/154) for those assigned to SIM+SUB (table 5); and 7% 
(10/135) and 11% (13/118) among patients who had 
undergone surgery allocated to radiotherapy alone or 
SIM alone, respectively.
There were 12 treatment-related deaths, largely 
associated with dehydration, necrosis, mucositis, 
dysphagia, and renal failure. Deaths were broken down 
by treatment group as follows: SIM alone (n=1), SUB 
alone (n=2), SIM+SUB (n=8), and radiotherapy alone 
(n=1). The ﬁ rst six deaths were sent for independent 
review, after which clearer instructions were given to 
patients regarding adequate hydration and, in some 
centres, the avoidance of non-steroidal anti-inﬂ ammatory 
agents (recognised to reduce glomerular ﬁ ltration rate). 
Among the eight deaths in the SIM+SUB group, two 
occurred during SIM treatment, ﬁ ve occurred after 
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Figure 3: Event-free survival (EFS) according to treatment groups for patients who had no surgery (A) and 
those who had undergone surgery (B) before randomisation
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. 
SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy.
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completing radiotherapy but before starting SUB (four of 
which occurred at least 1 month after ﬁ nishing SIM), and 
one occurred during SUB. 
Discussion 
The UKHAN1 trial is one of the largest in head and neck 
cancer, and, to our knowledge, the only study to examine 
the timing of chemotherapy (concurrent or maintenance) 
in a factorial design. Compared with radiotherapy alone, 
two courses of non-platinum chemotherapy given 
concurrently with radiotherapy (SIM alone) in patients 
without previous surgery signiﬁ cantly extended EFS by 
1·2 years (median EFS 2·2 vs 1·0 years; p=0·004). The 
diﬀ erence in overall survival of 2·1 years (median 4·7 vs 
2·6 years, p=0·09) was not statistically signiﬁ cant, 
probably because there were fewer overall survival events 
compared with EFS in the analysis of SIM alone versus 
radiotherapy alone (293 deaths vs 322 EFS events) and 
the eﬀ ect size was smaller (HR of 0·82 vs 0·72). The 
outcomes for SIM alone were achieved with only one 
treatment-related death (0·6%), high compliance (92%), 
and acceptable toxicity rate (28%) during treatment. 
Importantly, we are able to report the long-term beneﬁ ts 
of SIM. Among every 100 patients treated with SIM 
alone, there were an estimated 10·6 fewer patients with a 
recurrence, new tumour, or death, 10 years later, 
compared with radiotherapy alone. Concurrent 
chemoradiotherapy used in our study did not beneﬁ t 
patients who had undergone previous surgery, and the 
acute toxicity rate doubled.
Chemotherapy after radiotherapy was ineﬀ ective, 
which could be due in part to the higher proportion of 
patients who did not comply with treatment. Reasons for 
non-compliance (table 2) were largely because of toxicity, 
deaths, or withdrawals (perhaps because some felt too 
unwell after radiotherapy to continue with therapy). 
Chemotherapy non-compliance was highest in the 
SIM+SUB group, and might also be due to patients not 
wanting to continue treatment after two courses of 
Deaths (any cause) Events (recurrence, new tumour, or death) Recurrences
5 years 10 years 5 years 10 years 5 years 10 years
SIM alone vs radiotherapy alone –7·3 (–17·8 to 3·9) –7·1 (–18·4 to 3·5) –12·1 (–22·9 to –1·4) –10·6 (–21·2 to –1·1) –11·0 (–22·8 to 1·7) –11·1 (–23·0 to 1·7)
Any SIM vs radiotherapy alone –2·6 (–11·7 to 6·8) –2·5 (–11·7 to 5·9) –7·4 (–16·4 to 1·2) –6·3 (–14·7 to 1·0) –6·7 (–16·7 to 3·8) –6·7 (–16·7 to 3·8)
SUB alone vs radiotherapy alone  3·4 (–7·5 to 14·3) 3·1 (–7·3 to 11·8) 1·3 (–8·8 to 10·1) 1·1 (–7·5 to 7·5) 2·0 (–10·0 to 13·6) 2·0 (–10·0 to 13·4)
Any SUB vs radiotherapy alone 2·8 (–6·4 to 12·1) 2·6 (–6·2 to 10·2) –0·7 (–9·3 to 7·2) –0·5 (–8·0 to 5·5) 0·1 (–10·0 to 10·2)  0·1 (–10·1 to 10·1)
Any SIM vs no SIM –8·4 (–12·2 to 4·0) –8·1 (–14·1 to –2·3) –8·1 (–15·9 to –0·5) –7·0 (–14·4 to –0·4) –7·4 (–16·3 to 1·8) –7·4 (–16·4 to 1·8)
Any SUB vs no SUB 5·9 (–2·2 to 14·0) 5·4 (–2·2 to 12·2) 4·3 (–3·4 to 11·5) 3·6 (–3·0 to 9·1) 4·7 (–4·3 to 13·7) 4·7 (–4·3 to 13·6)
SIM+SUB vs SIM alone 9·4 (2·9 to 21·2) 8·4 (–2·8 to 17·1) 8·7 (–3·1 to 20·1) 7·8 (–3·0 to 16·4) 9·0 (–4·6 to 22·8) 9·0 (–4·7 to 22·8)
SIM+SUB vs SUB alone –1·3 (–13·3 to 10·3) –1·3 (–13·1 to 9·2) –4·4 (–15·8 to 5·8) –3·8 (–14·4 to 4·6) –3·9 (–17·0 to 9·1) –3·9 (–17·1 to 8·9)
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing 
radiotherapy. Negative risk diﬀ erences indicate that the event rate is lower than in the comparison group (ie, more beneﬁ cial); positive diﬀ erences indicate that the event rate is higher. Any SIM=SIM or SIM+SUB. 
Any SUB=SUB or SIM+SUB. The diﬀ erences were estimated by applying the hazard ratios (HR) and CI to the 5-year or 10-year rate in the comparison group. Diﬀ erence=exp[HR×ln(R1)]–R1. For example, HR could 
be the HR when comparing SIM to RT alone, and R1 the cumulative survival rate for the “RT alone” group at 10 years.
Table 4: Estimated absolute risk diﬀ erences (99% CI) 5 and 10 years after randomisation, among patients without previous surgery
No surgery Surgery
Radiotherapy 
alone 
(N=233)
SIM 
alone 
(N=166)
SUB 
alone 
(N=160)
SIM+SUB 
(N=154)
Radiotherapy 
alone 
(N=135)
SIM 
alone 
(N=118)
During treatment (requiring hospitalisation)
Mucositis 23 (10) 43 (26) 14 (9) 46 (30) 9 (7) 20 (17)
Candidiasis 8 (3) 8 (5) 2 (1) 7 (5) 1 (<1) 2 (2)
Renal failure 0 0 0 2 (1) 0 0
Septicaemia 0 1 (<1) 0 2 (1) 0 1 (1)
Reaction to methotrexate/VBMF 0 0 2 (1) 2 (1) 0 2 (2)
Radiation pharyngitis 0 0 0 0 2 (1) 0
Transient ischaemic attack 0 0 1 (<1) 0 1 (<1) 0
Other 2 (<1) 3 (2) 2 (1) 11 (7) 1 (<1) 3 (3)
According to chemotherapy
VBMF* n/a 16 (35) 4 (9) 20 (45) n/a 5 (18)
Methotrexate* n/a 31 (26) 15 (13) 35 (32) n/a 19 (21)
Any toxicity† 25 (11) 47 (28) 19 (12) 55 (36) 12 (9) 24 (20)
Occurring at least 6 months after randomisation
Xerostomia 6 (3) 2 (1) 2 (1) 3 (2) 2 (1) 3 (3)
Trismus 0 0 0 0 0 2 (2)
Mucositis 1 (<1) 0 1 (<1) 0 1 (<1) 0
Dysphagia 0 3 (2) 1 (<1) 2 (1) 1 (<1) 5 (4)
Fibrosis 0 1 (<1) 0 0 0 2 (2)
Stricture 1 (<1) 0 0 3 (2) 4 (3) 3 (3)
Other 5 (2) 4 (2) 5 (3) 2 (1) 2 (1) 4 (3)
According to chemotherapy
VBMF* n/a 6 (13) 2 (4) 5 (11) n/a 3 (11)
Methotrexate* n/a 4 (3) 5 (4) 4 (4) n/a 10 (11)
Any toxicity† 13 (6) 10 (6) 7 (4) 9 (6) 10 (7) 13 (11)
SIM=radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy. 
SUB= radiotherapy with two courses of chemotherapy given 14 and 28 days after completing radiotherapy. n/a=not 
applicable. Data are n(%). VBMF=vincristine, bleomycin, methotrexate, and ﬂ uorouracil. Patients could have more 
than one toxicity. *Expressed as a percentage of those allocated to VBMF or methotrexate (webappendix). †Each 
patient counted once.
Table 5: Toxicities reported during treatment and at least 6 months after randomisation according to 
trial group
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chemotherapy, possibly because they had completely 
responded after simultaneous chemoradiation, or were 
too unwell to continue. Furthermore, overall survival and 
EFS were worse in the SIM+SUB group than with SIM 
alone.
UKHAN1 centres were allowed to choose the 
radiotherapy regimen. This is because when the trial was 
designed in 1989 there was concern over the potential 
toxic interaction between radiotherapy and one or more 
of the chemotherapy groups. Data were emerging that 
gaps in radiotherapy were detrimental in patients with 
squamous-cell carcinomas, and so should be avoided. We 
therefore allowed a range of regimens that would be 
tolerated by most patients, making them less likely to 
require rests from radiotherapy due to chemotherapy 
toxicity. Furthermore, this was a pragmatic trial, so we 
wanted centres to give their normal radiotherapy to 
encourage clinicians to participate, and therefore the 
doses used represented those given in routine practice at 
the time. All the radiotherapy regimens were radical 
doses, and there was no evidence that the radiotherapy 
regimen used aﬀ ected EFS (webappendix).
There is variation in how patients with head and neck 
cancer are treated, with no established and agreed policy 
on chemoradiation, including for patients judged unﬁ t for 
platinum therapy. After the ﬁ rst MACH-NC meta-analysis 
of chemotherapy in head and neck cancer,6 the beneﬁ t 
from routine chemotherapy remained unclear. However, 
in the recent update, based on 9615 patients and including 
older data from UKHAN1, concomitant chemotherapy led 
to statistically signiﬁ cant reductions in deaths and 
recurrences,7 with point estimates similar to those from 
UKHAN1: HR for overall survival 0·81 in MACH-NC 
versus 0·82 (99% CI 0·60–1·11) in UKHAN1, and HR for 
EFS 0·79 in MACH-NC versus 0·72 (99% CI 0·53–0·96) 
in UKHAN1 (MACH-NC used recurrence-free survival 
instead of EFS). MACH-NC also conﬁ rmed that adjuvant 
chemotherapy is ineﬀ ective (overall survival HR 0·99, 
95% CI 0·89–1·10, in 2567 patients). The review was based 
on adding chemotherapy to any loco-regional treatment 
(ie, a mixture of surgery, no surgery, radiotherapy using 
standard or hyperfractionated regimens, or pre-operative 
radiotherapy). UKHAN1 clearly separates patients 
according to whether they had surgery or not, showing 
that concurrent non-platinum chemotherapy used in 
the trial was more eﬀ ective than radiotherapy alone in the 
non-surgical group, but not in the group that had 
undergone previous surgery. Additionally, our results are 
based on patients with a median follow-up of 10 years, 
compared with 5·6 years in the meta-analysis. Finally, our 
study provides direct randomised evidence on the timing 
of chemotherapy (ie, comparing concurrent with 
maintenance chemotherapy). 
The MACH-NC meta-analysis showed that concurrent 
chemoradiation should now be the routine treatment of 
choice for all patients with non-surgically treated 
advanced head and neck cancer. The UKHAN1 study 
conﬁ rms this, but it also shows that a long-term beneﬁ t 
in terms of recurrence and deaths could be achieved with 
non-platinum agents that are inexpensive, relatively easy 
to deliver, and have lower toxicity than platinum therapies. 
Very few randomised head and neck cancer trials have 
reported such long-term eﬀ ects of chemo-radiotherapy, 
and we are not aware of any that have also investigated 
concurrent platinum treatment. 
Cisplatin used concurrently with radical radiotherapy 
has been shown to be better than radiotherapy alone: in an 
EORTC trial (334 post-surgical patients with locally 
advanced disease), the risk of death was reduced by 30% 
(p=0·02).12 EFS was improved with cisplatin in a RTOG 
trial (459 high-risk patients who had complete resection), 
with a decrease in risk (HR 0·78, 95% CI 0·61–0·99; 
p=0·04).13 However, acute toxicity rates were much higher 
in those receiving chemotherapy (77% RTOG and 41% 
EORTC), compared with that in our own trial using VBMF 
or methotrexate (28%). Although cisplatin-based regimens 
are often used in the US, the MACH-NC meta-analysis 
did not ﬁ nd a survival diﬀ erence according to type of 
chemotherapy (p=0·42). In trials of poly-chemotherapy, 
the HR for death was 0·75 (95% CI 0·67–0·84; using both 
ﬂ uorouracil and platinum), 0·83 (0·74–0·94; using either 
ﬂ uorouracil or platinum), and 0·73 (0·52–1·01; using 
chemotherapy other than ﬂ uorouracil or platinum); the 
UKHAN1 estimate was 0·82.
Newer agents such as taxanes and targeted therapies 
might improve on the longer-established doublet of 
cisplatin and ﬂ uorouracil.14–16 Bonner and colleagues were 
the ﬁ rst to show the value of cetuximab in advanced head 
and neck cancer, with a 30% reduction in the number of 
patients who progress or die (in a trial of 424 patients).16 
Similar therapy combinations continue to be investigated. 
However, the potential late morbidity of combination 
chemo radio therapy, including secondary tumours, 
should be monitored. Our 10-year follow-up is reassuring 
for the regimens used in the UKHAN1 study, and should 
encourage other trials to follow patients for many years.
Hyperfractionated radiotherapy, involving an increase 
in the daily number of administered doses, is currently 
diﬃ  cult for many UK oncology departments to deliver, so 
the simpler two courses of chemotherapy with only one 
fraction per day using standard regimens seems more 
feasible. As with improved outcomes at other sites such 
as the cervix, anus and lung, radical simultaneous 
chemoradiation therapy for SCC of the head and neck is 
an eﬀ ective way of treating these life-threatening and 
disabling diseases.
Human papillomavirus (HPV) status was not obtained 
during the trial because it was not recognised as being a 
useful factor in head and neck cancer at the time the 
study was designed. However, data are beginning to 
emerge suggesting that patients with HPV-positive 
tumours have a better prognosis.17 Although most 
evidence comes from observational studies, the eﬀ ects 
have been seen in retrospective analyses of randomised 
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trials.18,19 We plan to examine HPV status and its possible 
eﬀ ect on outcome in the UKHAN1 trial in the future.
In summary, UKHAN1 showed that patients with head 
and neck cancer who had undergone previous surgery did 
not beneﬁ t from the addition of chemotherapy to 
adjunctive post-operative radiotherapy. However, there 
was a clear beneﬁ t on recurrences and deaths associated 
with two courses of simultaneous non-platinum 
chemoradiotherapy in patients who had not undergone 
previous surgery, and this beneﬁ t persisted after a long 
follow up. Non-platinum-based chemotherapy could be 
considered an alternative to platinum-based regimens, as 
well as an eﬀ ective therapy for patients who are judged to 
be unﬁ t for cisplatin. With this particular group of patients, 
characteristically with multiple comorbidity and relatively 
low compliance to chemo therapy, the inability to tolerate 
platinum-based regimens is often a serious barrier to 
radical chemoradiation. Moreover, the avoidance of local 
recurrence, with its potentially devastating consequences 
for the patient’s quality of life, is of particular importance 
in this group, many of whom suﬀ er from social deprivation 
and poor domestic support. Improving EFS reduces the 
number of patients who later need radical salvage surgery, 
which can be associated with long-term or permanent 
disﬁ gurement, impaired function (eg, ability to speak or 
eat easily), or social exclusion.20 Because this is a high risk 
and generally unﬁ t patient group, many of whom are 
excessive users of alcohol and tobacco throughout 
treatment, the availability of a relatively simple, inexpensive 
and low toxicity chemoradiation regimen considerably 
improves the likelihood of completing treatment, essential 
for improving the chance of cure.
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